This is a regional conference that has been sponsored by the University of Nebraska Medical Center for the last 13 years. The conference is designed to update the target audience on new treatments and management of acute and chronic leukemia, thrombosis/hemostasis, lymphoma, multiple myeloma, myelodysplastic syndromes, and myeloproliferative neoplasms as presented during the 2019 annual meeting of the American Society of Hematology. Presentations will be delivered by key leaders while allowing the opportunity for participants to be involved in the interactive question/answer sessions.

Target Audience

These activities are intended for physicians, nurse practitioners, physician assistants, nurses, residents, and fellows in the specialty areas of oncology, hematology, internal medicine, radiation oncology, and pathology.

Conference Objectives

At the conclusion of these activities, the participant should be able to:

1. Review the rationale and mechanism of action for CAR T-cell therapy, as well as outcomes and side effects
2. Provide an update on the use of novel therapies for hematologic malignancies, as well as non-malignant hematologic disorders
3. Discuss recent trials of therapy for hematologic malignancies including lymphoma, acute and chronic leukemia, myelodysplastic syndromes, myeloproliferative neoplasms, and multiple myeloma
4. Review emerging data regarding new clinical, genetic, and molecular prognostic factors, and how to use them for precision approaches for the treatment of hematologic malignancies
5. Discuss treatment results from using new-targeted agents, CAR T-cell therapy, and other immunotherapies for hematologic malignancies, as well as their mechanism of action and toxicities
6. Discuss recent trials of therapy and new agents for hemostasis and thrombosis
7. Describe the role of autologous and allogeneic hematopoietic stem cell transplantation for various hematologic malignancies
8. Use the findings from the 2019 ASH meeting to apply evidence-based medicine into the management of hematologic malignancies and disorders of thrombosis and hemostasis

Continuing Education Credit

The University of Nebraska Medical Center, Center for Continuing Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

The University of Nebraska Medical Center College of Nursing Continuing Nursing Education is accredited with distinction as a provider of nursing continuing professional development by the American Nurses Credentialing Center’s Commission on Accreditation.

Lymphoma Study Group
The University of Nebraska Medical Center, Center for Continuing Education designates this live activity for a maximum of 1 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

This activity is provided for 1.0 contact hour under ANCC criteria.

Hematology Highlights: A Post ASH Review
The University of Nebraska Medical Center, Center for Continuing Education designates this live activity for a maximum of 4 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

This activity is provided for 4.0 contact hours under ANCC criteria.

Fore more information, or to register, please visit the conference website.